Show simple item record

dc.contributor.authorNash, Peter
dc.contributor.authorMcInnes, Iain B
dc.contributor.authorMease, Philip J
dc.contributor.authorThom, Howard
dc.contributor.authorHunger, Matthias
dc.contributor.authorKarabis, Andreas
dc.contributor.authorGandhi, Kunal
dc.contributor.authorMpofu, Shephard
dc.contributor.authorJugl, Steffen M
dc.date.accessioned2020-07-31T01:20:30Z
dc.date.available2020-07-31T01:20:30Z
dc.date.issued2018
dc.identifier.issn2198-6576
dc.identifier.doi10.1007/s40744-018-0106-6
dc.identifier.urihttp://hdl.handle.net/10072/395987
dc.description.abstractINTRODUCTION: Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. METHODS: Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs. placebo; N = 313). Logistic regression determined adjustment weights for age, body weight, sex, race, methotrexate use, psoriasis affecting ≥ 3% of body surface area, Psoriasis Area and Severity Index score, Health Assessment Questionnaire Disability Index score, presence of dactylitis and enthesitis, and previous anti-TNF therapy. Recalculated secukinumab outcomes were compared with adalimumab outcomes at weeks 12 (placebo-adjusted), 16, 24, and 48 (nonplacebo-adjusted). RESULTS: After matching, the effective sample size for FUTURE 2 was 101. Week 12 American College of Rheumatology (ACR) response rates were not significantly different between secukinumab and adalimumab. Week 16 ACR 20 and 50 response rates were higher for secukinumab 150 mg than for adalimumab (P = 0.017, P = 0.033), as was ACR 50 for secukinumab 300 mg (P = 0.030). Week 24 ACR 20 and 50 were higher for secukinumab 150 mg than for adalimumab (P = 0.001, P = 0.019), as was ACR 20 for secukinumab 300 mg (P = 0.048). Week 48 ACR 20 was higher for secukinumab 150 and 300 mg than for adalimumab (P = 0.002, P = 0.027), as was ACR 50 for secukinumab 300 mg (P = 0.032). CONCLUSIONS: In our analysis, patients with PsA receiving secukinumab were more likely to achieve higher ACR responses through 1 year (weeks 16-48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from FUTURE 2 and thus should be considered interim until the ongoing head-to-head RCT EXCEED can validate these findings. FUNDING: Novartis Pharma AG.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofpagefrom99
dc.relation.ispartofpageto122
dc.relation.ispartofissue1
dc.relation.ispartofjournalRheumatology and Therapy
dc.relation.ispartofvolume5
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsRheumatology
dc.subject.keywordsAdalimumab
dc.subject.keywordsComparative effectiveness
dc.titleSecukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationNash, P; McInnes, IB; Mease, PJ; Thom, H; Hunger, M; Karabis, A; Gandhi, K; Mpofu, S; Jugl, SM, Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison, Rheumatology and Therapy, 2018, 5 (1), pp. 99-122
dcterms.licensehttp://creativecommons.org/licenses/by-nc/4.0/
dc.date.updated2020-07-31T01:00:58Z
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
gro.hasfulltextFull Text
gro.griffith.authorNash, Peter


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record